Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-02-25
2000-03-28
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546149, C07D21700, A61K 3147
Patent
active
060432535
ABSTRACT:
Fused piperidine substituted arylsulfonamides are .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
REFERENCES:
patent: 4999377 (1991-03-01), Caulkett et al.
patent: 5017619 (1991-05-01), Alig et al.
patent: 5153210 (1992-10-01), Ainsworth et al.
patent: 5294621 (1994-03-01), Russell
patent: 5451677 (1995-09-01), Fisher et al.
Konar, AA et al, Eur. J. Pharmacol., 1996, 305:63-71.
Konar, AA et al, American Society for Pharmacology and Experimental Therapeutics, Mar. 1997 Meeting Abstract No. 142.
He, et al. J. of China Pharm. University, vol. 29, No. 3, pp. 157-160, 1998 .
Brockunier Linda
Parmee Emma R.
Weber Ann E.
Davis Zinna Northington
Merck & Co. , Inc.
Rose David L.
Yang Mollie M.
LandOfFree
Fused piperidine substituted arylsulfonamides as .beta.3-agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused piperidine substituted arylsulfonamides as .beta.3-agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused piperidine substituted arylsulfonamides as .beta.3-agonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1326303